Publication

An anticancer drug suppresses the primary nucleation reaction that initiates the production of the toxic Aβ42 aggregates linked with Alzheimer's disease

Habchi, J., Arosio, P., Perni, M., Costa, A. R., Yagi-Utsumi, M., Joshi, P., Chia, S., Cohen, S. I. A., Müller, M. B. D., Linse, S., Nollen, E. A. A., Dobson, C. M., Knowles, T. P. J. & Vendruscolo, M., 12-Feb-2016, In : Science Advances. 2, 2, 13 p., e1501244.

Research output: Contribution to journalArticleAcademicpeer-review

  • Johnny Habchi
  • Paolo Arosio
  • Michele Perni
  • Ana Rita Costa
  • Maho Yagi-Utsumi
  • Priyanka Joshi
  • Sean Chia
  • Samuel I A Cohen
  • Martin B D Müller
  • Sara Linse
  • Ellen A A Nollen
  • Christopher M Dobson
  • Tuomas P J Knowles
  • Michele Vendruscolo

The conversion of the β-amyloid (Aβ) peptide into pathogenic aggregates is linked to the onset and progression of Alzheimer's disease. Although this observation has prompted an extensive search for therapeutic agents to modulate the concentration of Aβ or inhibit its aggregation, all clinical trials with these objectives have so far failed, at least in part because of a lack of understanding of the molecular mechanisms underlying the process of aggregation and its inhibition. To address this problem, we describe a chemical kinetics approach for rational drug discovery, in which the effects of small molecules on the rates of specific microscopic steps in the self-assembly of Aβ42, the most aggregation-prone variant of Aβ, are analyzed quantitatively. By applying this approach, we report that bexarotene, an anticancer drug approved by the U.S. Food and Drug Administration, selectively targets the primary nucleation step in Aβ42 aggregation, delays the formation of toxic species in neuroblastoma cells, and completely suppresses Aβ42 deposition and its consequences in a Caenorhabditis elegans model of Aβ42-mediated toxicity. These results suggest that the prevention of the primary nucleation of Aβ42 by compounds such as bexarotene could potentially reduce the risk of onset of Alzheimer's disease and, more generally, that our strategy provides a general framework for the rational identification of a range of candidate drugs directed against neurodegenerative disorders.

Original languageEnglish
Article numbere1501244
Number of pages13
JournalScience Advances
Volume2
Issue number2
Publication statusPublished - 12-Feb-2016

    Keywords

  • chemical kinetics, molecular mechanisms, protein misfolding, neurodegeneration

View graph of relations

Download statistics

No data available

ID: 30155187